Adolescent and young adults with attention-deficit/hyperactivity disorder (ADHD) are at a higher risk for subsequent sexually transmitted infections (STIs), but taking medicine for ADHD can help cut the risk, according to research published in the Journal of the American Academy of Child and Adolescent Psychiatry.
Adolescent and young adults with attention-deficit/hyperactivity disorder (ADHD) are at a higher risk for subsequent sexually transmitted infections (STIs), but taking medicine for ADHD can help cut the risk, according to a study from Taiwan. Based on the findings, the authors made recommendations for clinicians, who may be reluctant to prescribe ADHD medicine for some patients.
The study was published in the January 2018 issue of the Journal of the American Academy of Child and Adolescent Psychiatry. The findings are based on the Taiwan National Health Insurance Research Database, which is a nationally representative database of medical claims and healthcare data.
The study included 17,898 adolescents and young adults diagnosed with ADHD and 71,592 age and sex-matched non-ADHD controls who did not have STIs prior to enrollment. Adolescents aged 12 to 17 years and young adults aged 18 to 29 years were followed from January 1, 2001, through the end of 2009.
The researchers tracked data related to risk of STIs, including HIV, syphilis, genital warts, gonorrhea, chlamydial infection, and trichomoniasis, as well as the presence of other psychiatric conditions. They also measured whether subjects were taking methylphenidate or atomoxetine for ADHD. Short-term use of medicine was defined as taking medicine between 30 and 364 days, and long-term use was defined as more than 365 days.
Findings included:
The researchers wrote that the differences in the risk of STIs between male and female patients with ADHD require additional study.
While previous studies have suggested that ADHD is related to risky sexual behaviors—a major STI risk factor—the link between ADHD and subsequent STIs has been unknown. The authors said there were several possible explanations for the findings, as previous studies have discussed how the main symptoms of ADHD, as well as certain comorbidities, relate to risky sexual behavior.
While the authors noted that some clinicians could have concerns about prescribing ADHD medications, especially psychostimulants, to patients with ADHD who also have a substance use disorder, they pointed to accumulating evidence indicating those concerns may be unfounded. Receiving ADHD medication is unlikely to be associated with a greater risk of substance-related problems in adolescence or adulthood, and the medicine is associated with lower concurrent risk of substance-related events.
The researchers suggested that healthcare providers focus on the increased risk of STIs for patients with ADHD and substance use disorders, and be “exceptionally diligent” in seeking treatment compliance with this high-risk group.
Several limitations were noted with this study.
Reference
Chen M, Hsu J, Huang K, et al. Sexually transmitted infection among adolescents and young adults with attention-deficit/hyperactivity disorder: a nationwide longitudinal study. J Am Acad Child Adolesc Psychiatry 2018;57(1):48—53.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More